Sports News

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 16,360,000 shares, a growth of 17.4% from the March 15th total of 13,930,000 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is currently 8.9 days.

Editas Medicine Stock Down 5.6 %

Shares of Editas Medicine stock traded down $0.37 during trading on Friday, reaching $6.21. The company’s stock had a trading volume of 2,024,621 shares, compared to its average volume of 1,880,755. The company has a 50-day simple moving average of $7.92 and a two-hundred day simple moving average of $8.44. Editas Medicine has a 1-year low of $6.08 and a 1-year high of $11.91. The company has a market cap of $508.04 million, a price-to-earnings ratio of -3.03 and a beta of 2.01.

Editas Medicine (NASDAQ:EDIT – Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.29. The business had revenue of $60.00 million during the quarter, compared to analysts’ expectations of $4.84 million. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The company’s revenue for the quarter was up 817.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.88) EPS. As a group, analysts anticipate that Editas Medicine will post -2.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on EDIT. JPMorgan Chase & Co. raised their price objective on Editas Medicine from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Tuesday, February 27th. StockNews.com upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Citigroup raised their price objective on Editas Medicine from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Finally, Barclays raised their price objective on Editas Medicine from $10.00 to $11.00 and gave the stock an “equal weight” rating in a report on Thursday, February 29th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Read Our Latest Stock Report on EDIT

Insider Activity

In other news, CEO Gilmore Neil O’neill sold 77,824 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total value of $733,102.08. Following the completion of the sale, the chief executive officer now directly owns 327,470 shares of the company’s stock, valued at approximately $3,084,767.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Baisong Mei sold 20,327 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $9.42, for a total value of $191,480.34. Following the sale, the senior vice president now directly owns 141,543 shares in the company, valued at $1,333,335.06. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Gilmore Neil O’neill sold 77,824 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total value of $733,102.08. Following the completion of the sale, the chief executive officer now owns 327,470 shares in the company, valued at $3,084,767.40. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Editas Medicine

Several institutional investors and hedge funds have recently modified their holdings of the stock. Los Angeles Capital Management LLC acquired a new position in shares of Editas Medicine in the 1st quarter valued at about $1,097,000. Virtu Financial LLC purchased a new position in shares of Editas Medicine in the 4th quarter valued at about $748,000. Public Employees Retirement System of Ohio purchased a new position in shares of Editas Medicine in the 4th quarter valued at about $137,000. Barclays PLC increased its stake in shares of Editas Medicine by 1.6% in the 4th quarter. Barclays PLC now owns 279,437 shares of the company’s stock valued at $2,831,000 after purchasing an additional 4,421 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in shares of Editas Medicine in the 4th quarter valued at about $5,626,000. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

See Also

Before you consider Editas Medicine, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Editas Medicine wasn’t on the list.

While Editas Medicine currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Related Articles

Leave a Reply

Back to top button